Here are three things to know.
- Vyxeos is a fixed-combination therapy containing two chemotherapy drugs.
- The drug is intended to treat adults with two types of high-risk AML.
- In a recent clinical trial, patients taking Vyxeos had a median overall survival of 9.56 months, compared to 5.95 months for those receiving the two chemotherapy drugs separately.
More articles on supply chain:
Device recalls fall in Q2, drug recalls rise: 10 report findings
Woman sues CVS over generic drug co-pay ‘clawbacks’
Fujifilm recalls duodenoscopes over infection risk
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
